Sign In
Buy SAN
$14.10
-0.0100 (-0.0709%)
At Close: Jul 31, 2026
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
07:00am, Thursday, 05'th Jan 2023 GlobeNewswire Inc.
FDA accepts nirsevimab application as first protective option against RSV disease for all infants
Santander and Global Payments Team on Commercial Bank Card
05:13pm, Wednesday, 04'th Jan 2023
Santander Bank said it's working with Global Payments on a card offering for corporate clients. In a LinkedIn post on Wednesday (Jan. 4), Santander said that starting in early 2023, its U.S. commer
Communiqué de presse: Mise en ligne du document «Q4 2022 Memorandum for modelling purposes»
06:30am, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
Mise en ligne du document «Q4 2022 Memorandum for modelling purposes»
Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
06:30am, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
Availability of the Q4 Memorandum for modelling purposes
Can XRP (Ripple) Reach $5 in 2023?
01:21pm, Wednesday, 28'th Dec 2022 The Motley Fool
As expected, the international payment token never crossed the $5 line in 2022. Next year may be a different story.
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
10:30pm, Wednesday, 21'st Dec 2022 GlobeNewswire Inc.
Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
Communiqué de presse: Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of Medicine
10:30pm, Wednesday, 21'st Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of Medicine
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
Sanofi: Informations relatives au nombre de droits de vote et d'actions Novembre 2022
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Communiqué de presse: Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie
Sanofi: Information concerning the total number of voting rights and shares November 2022
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
12:30pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophiles
12:30pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophiles
Communiqué de presse: Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaire
06:00am, Thursday, 15'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
06:00am, Thursday, 15'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
